Remove Branding Remove Contract Manufacturing Remove Generic Drugs
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. Prices would be “a fraction of the $300 per vial prices charged by insulin manufacturers.”.

Insulin 328
article thumbnail

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

pharmaphorum

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products. The post FTC clears Mylan merger with Pfizer’s Upjohn – with conditions appeared first on.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Hospital products, which grew 10% operationally to $2.3 down 7%, which reflects relatively stable U.S.